In this study, it was our intent to leverage discovery proteomics and informatics to identify HLA class I-presented peptide antigens, including common driver oncogenes, variant peptides, CG antigen peptides, PTM peptides, and lncRNA-translated peptides for immunotherapy in EGFR-mutant lung adenocarcinoma, a tumor type that is historically less responsive to immune checkpoint inhibitor therapy for variety of reasons, including low TMB. Here, EGFR is linked to neoplasm.